Our results suggest the possible benefit of an active IL-18 in the pathophysiology of pulmonary fibrosis and warrant analysis of IL-18 as a promising biomarker for predicting outcome in IPF patients. This evidence concerns the gene IL18 and idiopathic pulmonary fibrosis.